Verastem, Inc. (NASDAQ:VSTM) Given Average Rating of “Moderate Buy” by Analysts

Verastem, Inc. (NASDAQ:VSTM) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $15.8333.

VSTM has been the subject of a number of research reports. Royal Bank Of Canada set a $13.00 price objective on Verastem and gave the company an “outperform” rating in a research report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Verastem in a research note on Wednesday, January 21st. Cantor Fitzgerald raised shares of Verastem to a “strong-buy” rating in a research report on Thursday, October 30th. Guggenheim reiterated a “buy” rating on shares of Verastem in a research note on Tuesday, December 30th. Finally, Wall Street Zen lowered shares of Verastem from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th.

Verastem Price Performance

Shares of VSTM opened at $6.67 on Friday. The firm has a fifty day simple moving average of $7.75 and a two-hundred day simple moving average of $8.28. The firm has a market cap of $445.40 million, a PE ratio of -1.66 and a beta of 0.41. The company has a current ratio of 2.58, a quick ratio of 2.55 and a debt-to-equity ratio of 2.06. Verastem has a 1-year low of $4.01 and a 1-year high of $11.24.

Insider Buying and Selling at Verastem

In related news, Director Paul A. Bunn sold 6,250 shares of Verastem stock in a transaction on Friday, November 21st. The stock was sold at an average price of $10.00, for a total transaction of $62,500.00. Following the transaction, the director directly owned 2,083 shares in the company, valued at approximately $20,830. The trade was a 75.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel Calkins sold 5,039 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $7.16, for a total value of $36,079.24. Following the sale, the chief financial officer directly owned 104,719 shares of the company’s stock, valued at $749,788.04. This represents a 4.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 50,478 shares of company stock worth $462,045. 2.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its stake in shares of Verastem by 182.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,578 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 2,960 shares during the period. BNP Paribas Financial Markets raised its stake in Verastem by 110.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,550 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 4,496 shares during the period. E Fund Management Co. Ltd. bought a new stake in Verastem during the 2nd quarter worth approximately $49,000. Nebula Research & Development LLC purchased a new position in Verastem during the second quarter valued at approximately $53,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Verastem by 9.8% in the second quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 1,440 shares during the period. Institutional investors own 88.37% of the company’s stock.

More Verastem News

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 revenue came in stronger than investors expected, driven by sales from the Avmapki Fakzynja co‑pack partnership; the release prompted the near‑term stock rally. Verastem preliminary results
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and an $18 price target and updated long‑range EPS forecasts — notably raising FY2028 and FY2029 estimates and projecting much larger positive EPS by FY2030 — signaling growing analyst confidence in Verastem’s path to profitability. This analyst support likely amplified buying interest. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: CEO Dan Paterson filed a small sale of 970 shares at about $6.69 on Feb. 4; the sale is modest relative to his remaining holdings and likely has limited informational weight for investors. SEC filing
• Negative Sentiment: HC Wainwright’s near‑term forecasts still show multi‑year losses (FY2025–FY2027 and FY2026 EPS pegged negative), so while long‑term outlook is improving, the company remains unprofitable in the medium term — a risk for investors focused on near‑term cash burn or dilution. HC Wainwright estimates (MarketBeat)

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.